SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
复制标题
DOI：
10.2169/internalmedicine.4323-19
复制
发表时间：
2020-03
影响因子：
1.2
通讯作者：
K. Nonomura;K. Iizuka;Yayoi Kuwabara-Ohmura;D. Yabe
中科院分区：
文献类型：
--
作者：
K. Nonomura;K. Iizuka;Yayoi Kuwabara-Ohmura;D. Yabe
一名72岁的男性在54岁时被诊断患有2型糖尿病（T2 D）。大量白蛋白尿在64岁时首次被发现。虽然他的HbA 1c一直保持在7%以下，但他的估计肾小球滤过率（eGFR）迅速下降。70岁时，他的eGFR降至50 mL/min/1.73 m2以下。肾活检显示糖尿病肾病。钠葡萄糖转运蛋白2抑制剂（SGLT 2 i）/胰高血糖素样肽-1受体激动剂（GLP-1 RA）联合治疗显著改善了他的eGFR和尿白蛋白水平，并且肾脏保护作用持续两年研究期。这些结果表明，SGLT 2 i和GLP-1 RA可叠加改善T2 D患者的肾功能。
A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D.